Author Archives: Jan Paschal

Windward Bio (WWB Proposed), a Swiss biotech developing long-acting drug candidates to treat asthma, COPD and atopic dermatitis, unveiled the terms early today (Monday, Nov. 9,2026) for its $175 million IPO. Windward Bio is offering 10.29 million shares at a price range of $16.00 to $18.00 to raise $174.93 million, if priced at the $17.00 […]

Two healthcare IPOs –  Rezera (RZRA Proposed), a biotech targeting peripheral artery disease (PAD), and vVardis Holding AG (VVVV Proposed), a dental products start-up backed by PE player Apollo – are set for pricing this week – the week of Nov. 9, 2026 – to raise a total of $414.3 million. The Street, though, is […]

vVardis Holding AG (VVVV Proposed), a dental products start-up backed by Apollo,  launched its $214.3 million IPO on Friday afternoon – Nov. 6, 2026. The deal is set to price next week.  vVardis, based in Zug, Switzerland, is offering 9.52 million shares at a price range of $21.00 to $24.00 to raise $214.29 million, if […]

Rezera Inc. (RZRA Proposed), a Boston biotech planning a Phase 3 trial in 2027 of its leading drug candidate to treat peripheral artery disease (PAD), unveiled the terms for its $200 million IPO early today – Thursday, Nov. 5, 2026 – in an S-1/A filing. Rezera is offering 16.67 million shares at a price range […]

The IPO market is in slow-mo mode as November gets under way. No IPOs are scheduled to price this week. That’s not surprising, considering the U.S. stock market’s plunge on Friday,Oct. 30 – marking the Nasdaq’s worst month since March 2025 – and the mid-term U.S. elections tomorrow – on Tuesday, Nov. 3, 2026. The […]

OPay Ltd. (OPAY), the Nigerian FinTech app, has postponed its IPO indefinitely after the stock did not start trading today, as expected, according to Street sources familiar with the situation, IPOScoop has learned. Clients of a major firm have been notified that it was withdrawing from the IPO. It’s highly unusual for an IPO to […]

Aspen Neuroscience (ASPE), a biotech developing a stem cell therapy to treat patients with Parkinson’s Disease, priced its IPO at $15.00 – the low end of its range – and sold 9.375 million shares – the number in the prospectus – to raise $140.63 million on Thursday night, Oct. 29, 2026. The San Diego-based biotech’s […]

SoftBank-backed OPay Ltd  (OPAY), the parent of Nigeria’s No. 1 digital banking platform, priced its IPO at $19.00 – the low end of its range – and sold 16 million American Depositary Shares (ADS) to raise $304 million on Thursday night, Oct. 29, 2026. Each ADS represents 10 ordinary shares. Fast forward to Friday afternoon: […]

Bambusa Therapeutics (BBTX) upsized its IPO at pricing to 10.55 million shares – up from 9.38 million shares – and priced the IPO at $16.00 – the mid-point of its range – to raise $168.8 million on Thursday night, Oct. 29, 2026. The Boston biotech’s stock slid in its NASDAQ debut – opening at $14.88 […]

BHAV Acquisition Corp. II (BHAIU) raised $100 million tonight – becoming the second SPAC IPO in the $100 million club to get priced this week. Piscataway, N.J.-based BHAV Acquisition II priced 10 million units at $10.00 each to raise $100 million on Wednesday night, Oct. 28, 2026, according to its SEC filing and the company’s […]